Weave vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 43)
Weave logo

Weave

EmergingHealthcare

General

Patient communication platform serving 27K healthcare practices; VoIP, SMS reminders, and review management integrated with 100+ practice management systems.

AI VisibilityBeta
Overall Score
C43
Category Rank
#331 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
43
Gemini
39

About

Weave is a customer communication and engagement platform serving small and medium-sized healthcare practices including dental, optometry, veterinary, and medical offices. Founded in 2008 and headquartered in Lehi, Utah, Weave combines a VoIP phone system with patient communication tools — appointment reminders, recall campaigns, two-way texting, online review requests, and digital forms — into a single integrated platform. The company went public on the NYSE in November 2021.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

43
Overall Score
90
#331
Category Rank
#2
80
AI Consensus
83
stable
Trend
stable
39
ChatGPT
92
43
Perplexity
93
39
Gemini
89
45
Claude
96
46
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.